FROM VALUE TO PRICE: WHAT SHOULD BE THE PATH FOR ORPHAN DRUGS?

被引：0
|
作者：
Ethgen, O. [1 ]
Hutchings, A. [2 ]
Rollet, P. [3 ]
Standaert, B. [4 ]
机构：
[1] Univ Liege, Liege, Belgium
[2] GMAS, London, England
[3] GlaxoSmithKline Inc, London, England
[4] GlaxoSmithKline Biol, Wavre, Belgium
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.178
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A31 / A31
页数：1
相关论文
共 50 条
  • [1] REIMBURSED PRICE OF ORPHAN DRUGS: A VALUE BASED FRAMEWORK
    Mincarone, P.
    Leo, C. G.
    Sabina, S.
    Tordrup, D.
    Taruscio, D.
    Kanavos, P.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A678 - A678
  • [2] ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?
    De Joannis, P. E.
    Borget, I
    [J]. VALUE IN HEALTH, 2019, 22 : S784 - S785
  • [3] Orphan drugs and the NHS: should we value rarity?
    McCabe, C
    Claxton, K
    Tsuchiya, A
    [J]. BRITISH MEDICAL JOURNAL, 2005, 331 (7523): : 1016 - 1019
  • [4] At what price should the domain of value be extended?
    Saives, Anne-Laure
    [J]. REVUE INTERNATIONALE PME, 2023, 36 (3-4): : 177 - 184
  • [5] VALUE-BASED PRICE FORECASTING: AN ACCURATE METHOD FOR ORPHAN DRUGS?
    Anstee, K.
    Jao, R.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S266 - S267
  • [6] PREDICTING VALUE AND PRICE OF ORPHAN DRUGS: A COMPARISON ACROSS EUROPE AND THE US
    Ganesh, S.
    Anstee, K.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S382 - S382
  • [7] ORPHAN DRUGS: WHAT IS THE IMPACT OF SPECIAL PROVISIONS IN VALUE ASSESSMENT?
    Epstein, M.
    Michel, S.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S508 - S508
  • [8] HOW SHOULD WE VALUE ORPHAN DRUGS? SUGGESTIONS FROM A LARGE PUBLIC OPINION SURVEY
    Korchagina, D.
    Toumi, M.
    Aballea, S.
    Millier, A.
    Falissard, B.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A564 - A565
  • [9] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [10] PRICE NEGOTIATIONS FOR ORPHAN DRUGS IN GERMANY
    Ecker, T.
    Bot, D.
    Campion, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A601 - A601
12345